This week’s Monday Deal Review has a full set of equity deals from shelf to launch to close, one new U.S. registration and one deregistration to match, and some ideas for what to do with your debt (!), all
Ready, Set, Go, Close….
Oncogenex (NASDAQ: OGXI) put up a new shelf registration statement, although they said they are not planning to use it to fund the OGX-011 Phase 3 trials that generated so much excitement this week.
DiagnoCure (TSX: CUR) launched a Canadian offering of common shares (the preliminary prospectus is on SEDAR) through a syndicate of agents co-led by National Bank Financial Inc. and Bloom Burton & Co. and including Desjardins Securities Inc.
Æterna Zentaris, Inc. (TSX: AEZ, NASDAQ: AEZS) closed the $10 million offering it launched last week.
You Put Your Helix In, You Take Your Neovasc Out…
Helix BioPharma Corp. (TSX, FSE: HBP), following its registration with the SEC in March, has commenced trading in the U.S. on the OTCQX International Market under the ticker symbol HXBPF.
Neovasc Inc. (TSXV: NVC), which had filed a 20-F registration statement last June, has decided not to pursue a U.S. listing.
Will Trade Debt for…
PharmaGap Inc. (TSX-V: GAP), no novice when it comes to debt-for-shares deals, announced that it is converting $215,201 owed to the National Research Council of Canada, issuing 1,434,676 common shares to NRC at $0.15 per common share. NRC will hold a total of 3.2% of PharmaGap’s common shares.
Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) amended its debt facility agreement with Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC), extending payments to July 1, 2010 from July 1, 2009, and maturity to June 1, 2012 from December 1, 2011. Labopharm is promising not to draw down the remaining US$5 million of the US$25 million credit facility; but is picking up $2.6 million from the National Bank of Canada.
3 responses so far ↓
Monday Deal Review: July 20, 2009 « The Cross-Border Biotech Blog // July 20, 2009 at 7:05 am |
[...] Securities Inc. gets $8,030 plus 50,190 warrants as finders fees. PharmaGap also noted that June’s shares-for-debt deal with the NRC has TSX-V approval but is waiting for sign-off from NRC’s legal and financial services [...]
Monday Deal Review: July 27, 2009 « The Cross-Border Biotech Blog // July 27, 2009 at 12:09 am |
[...] (NASDAQ: OGXI) didn’t waste much time using the new shelf they put up last month, announced and closed a $9.5 million registered direct offering of 475,000 common shares. The $20 [...]
Monday Biotech Deal Review: October 25, 2009 « The Cross-Border Biotech Blog // October 26, 2009 at 9:51 am |
[...] Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) followed June’s $10 million offering with another $5.5 million this week: 4.58 million common shares at $1.20 per share plus 5-year [...]